Wang, Wenyan http://orcid.org/0000-0003-0589-654X
Wang, Xiaofeng
Dong, Ying
Walling, David P.
Liu, Pinglan
Liu, Wanhui
Shi, Yanan
Sun, Kaoxiang
Clinical trials referenced in this document:
Documents that mention this clinical trial
Population Pharmacokinetic Analysis to Support and Facilitate Switching from Risperidone Formulations to Rykindo in Patients with Schizophrenia
https://doi.org/10.1007/s40120-024-00578-w
Documents that mention this clinical trial
Population Pharmacokinetic Analysis to Support and Facilitate Switching from Risperidone Formulations to Rykindo in Patients with Schizophrenia
https://doi.org/10.1007/s40120-024-00578-w
Documents that mention this clinical trial
Population Pharmacokinetic Analysis to Support and Facilitate Switching from Risperidone Formulations to Rykindo in Patients with Schizophrenia
https://doi.org/10.1007/s40120-024-00578-w
Funding for this research was provided by:
This study was sponsored by Luye Pharma
Article History
Received: 15 November 2023
Accepted: 2 January 2024
First Online: 20 January 2024
Declarations
:
: Wenyan Wang, Ying Dong, Pinglan Liu, Wanhui Liu, Yanan Shi, and Kaoxiang Sun are all current employees in Luye Pharma. Xiaofeng Wang is a former employee of ClinPharm Solutions LLC. The study sponsor was involved in the study design and data collection, analysis, and interpretation. Wenyan Wang, Xiaofeng Wang, Ying Dong, David P. Walling, Pinglan Liu, Wanhui Liu, Yanan Shi, and Kaoxiang Sun declare no conflicts of interest.
: The study was performed in accordance with the Helsinki Declaration of 1964. Each study protocol was reviewed and approved by independent institutional review boards/Ethics Committees (Quorum Review IRB for CT-1S01 trial; Compass IRB, LLC for CT-USA-104 and CT-USA-102 trials). All participants gave written informed consent prior to the initiation of study procedures.